Difficulties and uncertainties in diagnosis, measurement of severity, and staging are
common to all neurodegenerative diseases. In the past 10 years, substantial changes in …

Objectives This study provides a systematic review and meta-analysis of randomized
controlled trials (RCTs) investigating the safety and efficacy of lithium in amyotrophic lateral …

The French neurologist Jean-Marie Charcot (1825-1893) is acclaimed for his studies on the
motor system and unifying previously disparate entities into 1 disorder, amyotrophic lateral …

Over the past 10 years, in the 54 ALS long-term trials, survival was used as an endpoint in
28% of them. 1 Since the riluzole trials, which initiated this endpoint measure, nearly all the …

Riluzole is currently the only approved medication for amyotrophic lateral sclerosis (ALS).
While other potential neuroprotective agents have been tested in clinical trials, none has …

Third, site administration costs can be covered, which addresses a barrier for patients
seeking expanded access for hospitaladministered drugs. Fourth, by focusing on drugs that …

To be fully prepared for the emergence of neuroprotective drugs in amyotrophic lateral
sclerosis (ALS), there is a clear need for the development of robust biomarkers for disease …

Spinal and bulbar muscular atrophy (SBMA), also known as Kennedy's disease, 1–3 is a
slowly progressive, X-linked motor neuron disease caused by a triplet repeat expansion in …

Amyotrophic lateral sclerosis is associated with degeneration in motor pathways, often with
extramotor involvement. Once symptoms develop, the disease is rapidly progressive, with a …

Despite the urgent, unmet clinical and economic need for treatment of neurodegenerative
diseases, trials of disease modifying drugs have produced little success. Amyotrophic lateral …